PROJECT NARRATIVE Through our published and preliminary data, we have identified a novel process by which expression of matrix metalloproteinase (MMP)-3 in acute lung injury/ARDS drives disease pathology. Our work will answer critical questions about why some patients resolve ARDS while others progress to life-threatening disease and by developing a therapeutic inhibitor of disease progression, as well as essential information about which patients and at what stages of disease progression therapeutic intervention will be most beneficial. Successful completion of these studies will advance our understanding of ARDS and provide a novel therapeutic approach for this devastating disorder.
|Effective start/end date||12/22/21 → 11/30/22|
- National Heart, Lung, and Blood Institute: $728,418.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.